News

The UK government has announced nearly £50 million in funding aimed at strengthening the NHS’s capacity to conduct commercial research projects and clinical trials supported partly by the pharmaceutical industry. The investment is intended to supply critical research and...

The Centers for Medicare & Medicaid Services (CMS) in the US has moved to extend the enrolment window for its GENEROUS pilot programme, an initiative aimed at introducing most-favoured-nation (MFN) pricing for outpatient drugs reimbursed by Medicaid. The agency...

Eli Lilly has launched what it describes as the most powerful AI factory wholly owned and operated by a pharmaceutical company, marking a significant expansion of advanced computing infrastructure in life sciences. The system, named LillyPod, was inaugurated in...

Periodontal disease has long been viewed primarily as a localized oral condition affecting the supporting structures of the teeth. However, growing evidence suggests that its impact extends well beyond the oral cavity. Chronic periodontal inflammation is increasingly recognized as a potential...

In 2026, the Pharmaceutical and Medical Device sectors face a "split-tier" EPR reality. Unlike general consumer goods, pharma has specific exemptions and unique traps that redefine how you handle your regulatory infrastructure for this niche. By leveraging the insights...

Novo Nordisk and Vivtex have formalised a collaboration aimed at advancing next-generation oral biologic therapies targeting obesity, diabetes and related comorbidities. Under the terms of the agreement, Vivtex will grant Novo Nordisk licences to selected oral drug-delivery technologies. In return,...

Addiction recovery has evolved into a multidisciplinary clinical domain where pharmacological interventions and holistic modalities increasingly coexist within structured treatment frameworks. As clinical evidence continues to validate both biochemical and behavioral pathways of recovery, treatment providers are adopting integrative...